Immune-related adverse events associated with programmed cell death protein-1 and programmed cell death ligand 1 inhibitors for non-small cell lung cancer: a PRISMA systematic review and meta-analysis

被引：0
|
作者：
Xiaoying Sun
Raheleh Roudi
Ting Dai
Shangya Chen
Bin Fan
Hongjin Li
Yaqiong Zhou
Min Zhou
Bo Zhu
Chengqian Yin
Bin Li
Xin Li
机构：
[1] Shanghai University of Traditional Chinese Medicine,Department of Dermatology, Yueyang Hospital of Integrated Traditional Chinese and Western Medicine
[2] Shanghai Academy of Traditional Chinese Medicine,Institute of Dermatology
[3] Iran University of Medical Sciences,Oncopathology Research Center
[4] Shandong Academy of Occupational Health and Occupational Medicine,Department of Toxicology
[5] Shandong Academy of Medical Science,Department of Pharmacology & Experimental Therapeutics
[6] Boston University School of Medicine,Department of Dermatology
[7] Shaanxi Traditional Chinese Medicine Hospital,undefined
来源：
BMC Cancer | / 19卷
关键词：
Non-small cell lung cancer; Oncology; Programmed cell death protein-1; Programmed cell death ligand 1; Inhibitor; Immune-related adverse event; Meta-analysis; Systematic review;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 50 条
  • [1] Immune-related adverse events associated with programmed cell death protein-1 and programmed cell death ligand 1 inhibitors for non-small cell lung cancer: a PRISMA systematic review and meta-analysis
    Sun, Xiaoying
    Roudi, Raheleh
    Dai, Ting
    Chen, Shangya
    Fan, Bin
    Li, Hongjin
    Zhou, Yaqiong
    Zhou, Min
    Zhu, Bo
    Yin, Chengqian
    Li, Bin
    Li, Xin
    BMC CANCER, 2019, 19 (1)
  • [2] Adverse cardiac events in the treatment of non-small cell lung cancer with programmed death-1and programmed death-ligand 1 inhibitors A protocol for systematic review and meta-analysis
    Li, Honglin
    Han, Deting
    Feng, Xiaoteng
    Yu, Wenjun
    Xu, Tongtong
    Ma, Tao
    Song, Lucheng
    MEDICINE, 2020, 99 (32) : E21613
  • [3] Immune-related and Common Adverse Events With Programmed Cell Death 1/Programmed Cell Death Ligand 1 inhibitors combined with other Anticancer Therapy for Solid Tumors: A Systematic Review and Meta-analysis
    Inoue, T.
    Narukawa, M.
    CLINICAL ONCOLOGY, 2025, 37
  • [4] Safety and efficacy of combination therapy using programmed cell death protein-1/programmed cell death ligand-1 inhibitors and radiotherapy in patients with non-small-cell lung cancer: A systematic review and meta-analysis
    Geng, Yichao
    Zhang, Qiuning
    Feng, Shuangwu
    Li, Chengcheng
    Wang, Lina
    Zhao, Xueshan
    Yang, Zhen
    Li, Zheng
    Luo, Hongtao
    Liu, Ruifeng
    Lu, Bing
    Wang, Xiaohu
    CANCER MEDICINE, 2021, 10 (04): : 1222 - 1239
  • [5] Fatal Adverse Events Associated With Programmed Cell Death Ligand 1 Inhibitors: A Systematic Review and Meta-Analysis
    Wang, Xuewen
    Wu, Shijie
    Chen, Yaying
    Shao, Erqian
    Zhuang, Tingting
    Lu, Linbin
    Chen, Xiong
    FRONTIERS IN PHARMACOLOGY, 2020, 11
  • [6] Prognostic significance of programmed cell death ligand 1 blood markers in non-small cell lung cancer treated with immune checkpoint inhibitors: a systematic review and meta-analysis
    Zhang, Ningning
    Chang, Jianlan
    Liu, Ping
    Tian, Xiangyang
    Yu, Junyan
    FRONTIERS IN IMMUNOLOGY, 2024, 15
  • [7] Incidence of Pneumonitis With Use of Programmed Death 1 and Programmed Death-Ligand 1 Inhibitors in Non-Small Cell Lung Cancer
    Khunger, Monica
    Rakshit, Sagar
    Pasupuleti, Vinay
    Hernandez, Adrian V.
    Mazzone, Peter
    Stevenson, James
    Pennell, Nathan A.
    Velcheti, Vamsidhar
    CHEST, 2017, 152 (02) : 271 - 281
  • [8] Fatal adverse events associated with programmed cell death protein 1 or programmed cell death-ligand 1 monotherapy in cancer
    Zhao, Bin
    Zhao, Hong
    Zhao, Jiaxin
    THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY, 2020, 12
  • [9] Programmed death-1 or programmed death ligand-1 inhibitors? A meta-analysis of differential efficacy as compared to chemotherapy in advanced non-small cell lung cancer
    Bozcuk, Hakan
    Artac, Mehmet
    Mutlu, Hasan
    Sever, Ozlem
    Yildirim, Mustafa
    JOURNAL OF ONCOLOGY PHARMACY PRACTICE, 2021, 27 (02) : 405 - 413
  • [10] The incidence of pseudoprogressive disease associated with programmed cell death 1/programmed cell death ligand 1 inhibitors A meta-analysis
    Zhang, Jingyi
    Tan, Kexin
    Jiang, Xuejiao
    Zheng, Shuyue
    Li, Jia
    Xue, Chongxiang
    Zhang, Xu
    Cui, Huijuan
    MEDICINE, 2021, 100 (28) : E26649
12345